Phase 1 Study of SL-172154 (SIRPĪ±-Fc-CD40L) in Subjects With Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 first in human, open label, multi-center, dose escalation study to evaluate
the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-172154 in
subjects with ovarian cancer.